New York State Common Retirement Fund’s Anavex Life Sciences AVXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $47.2K | Hold |
18,209
| – | – | ﹤0.01% | 3023 |
|
|
2026
Q1 | $55.9K | Hold |
18,209
| – | – | ﹤0.01% | 2787 |
|
|
2025
Q4 | $64.8K | Hold |
18,209
| – | – | ﹤0.01% | 2824 |
|
|
2025
Q3 | $162K | Hold |
18,209
| – | – | ﹤0.01% | 2391 |
|
|
2025
Q2 | $168K | Hold |
18,209
| – | – | ﹤0.01% | 2336 |
|
|
2025
Q1 | $156K | Hold |
18,209
| – | – | ﹤0.01% | 2332 |
|
|
2024
Q4 | $196K | Hold |
18,209
| – | – | ﹤0.01% | 2309 |
|
|
2024
Q3 | $103K | Hold |
18,209
| – | – | ﹤0.01% | 2569 |
|
|
2024
Q2 | $76.8K | Sell |
18,209
-11,092
| -38% | -$44.9K | ﹤0.01% | 2969 |
|
|
2024
Q1 | $149K | Sell |
29,301
-20
| -0.1% | -$113 | ﹤0.01% | 2574 |
|
|
2023
Q4 | $273K | Buy |
29,321
+2,670
| +10% | +$18.4K | ﹤0.01% | 2332 |
|
|
2023
Q3 | $175K | Buy |
26,651
+212
| +0.8% | +$1.69K | ﹤0.01% | 2484 |
|
|
2023
Q2 | $215K | Sell |
26,439
-12,857
| -33% | -$110K | ﹤0.01% | 2462 |
|
|
2023
Q1 | $337K | Sell |
39,296
-9,124
| -19% | -$91.1K | ﹤0.01% | 2374 |
|
|
2022
Q4 | $448K | Buy |
48,420
+4,201
| +10% | +$44.9K | ﹤0.01% | 2363 |
|
|
2022
Q3 | $456K | Buy |
44,219
+130
| +0.3% | +$1.37K | ﹤0.01% | 2371 |
|
|
2022
Q2 | $441K | Sell |
44,089
-79
| -0.2% | -$748 | ﹤0.01% | 2410 |
|
|
2022
Q1 | $544K | Buy |
44,168
+20
| +0% | +$246 | ﹤0.01% | 2367 |
|
|
2021
Q4 | $766K | Sell |
44,148
-104
| -0.2% | -$1.98K | ﹤0.01% | 2218 |
|
|
2021
Q3 | $794K | Sell |
44,252
-9,422
| -18% | -$188K | ﹤0.01% | 2222 |
|
|
2021
Q2 | $1.23M | Buy |
53,674
+11,074
| +26% | +$164K | ﹤0.01% | 2130 |
|
|
2021
Q1 | $637K | Buy |
42,600
+11,200
| +36% | +$122K | ﹤0.01% | 2331 |
|
|
2020
Q4 | $170K | Buy |
31,400
+3,600
| +13% | +$19K | ﹤0.01% | 2813 |
|
|
2020
Q3 | $126K | Hold |
27,800
| – | – | ﹤0.01% | 2832 |
|
|
2020
Q2 | $137K | Hold |
27,800
| – | – | ﹤0.01% | 2813 |
|
|
2020
Q1 | $88K | Hold |
27,800
| – | – | ﹤0.01% | 2809 |
|
|
2019
Q4 | $72K | Hold |
27,800
| – | – | ﹤0.01% | 3070 |
|
|
2019
Q3 | $88K | Sell |
27,800
-16,200
| -37% | -$46.7K | ﹤0.01% | 3064 |
|
|
2019
Q2 | $148K | Buy |
+44,000
| New | +$137K | ﹤0.01% | 2959 |
|
|
2018
Q2 | – | Sell |
-33,500
| Closed | -$92K | – | 3176 |
|
|
2018
Q1 | $92K | Hold |
33,500
| – | – | ﹤0.01% | 2966 |
|
|
2017
Q4 | $108K | Hold |
33,500
| – | – | ﹤0.01% | 2965 |
|
|
2017
Q3 | $139K | Hold |
33,500
| – | – | ﹤0.01% | 2929 |
|
|
2017
Q2 | $178K | Sell |
33,500
-1
| -0% | -$6 | ﹤0.01% | 2900 |
|
|
2017
Q1 | $192K | Buy |
33,501
+1
| +0% | +$5 | ﹤0.01% | 2784 |
|
|
2016
Q4 | $133K | Hold |
33,500
| – | – | ﹤0.01% | 2907 |
|
|
2016
Q3 | $122K | Hold |
33,500
| – | – | ﹤0.01% | 2936 |
|
|
2016
Q2 | $205K | Buy |
+33,500
| New | +$162K | ﹤0.01% | 2721 |
|
Other funds holding AVXL
SF
New York State Common Retirement Fund's AVXL Position: Q2 2026 in Review
New York State Common Retirement Fund held its Anavex Life Sciences (AVXL) position steady in Q2 2026 at 18,209 shares worth $47.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3023.
New York State Common Retirement Fund first reported a position in AVXL in Q2 2016 and has held it in 37 quarters since. The position peaked at $1.23M in Q2 2021. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.
- New York State Common Retirement Fund held 18,209 shares of Anavex Life Sciences worth $47.2K as of Q2 2026.
- New York State Common Retirement Fund left its Anavex Life Sciences share count unchanged in Q2 2026.
- Anavex Life Sciences made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #3023 holding.
- New York State Common Retirement Fund first reported a position in Anavex Life Sciences in Q2 2016 and has held it in 37 quarters since.
- New York State Common Retirement Fund's Anavex Life Sciences position peaked at $1.23M in Q2 2021.
- 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.
Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.